Effect of 12 neutralizing anti-cytokine antibodies on in vitro activation of B-cells. Interleukin-12 is required by B1a but not B2 cells

被引:11
作者
Jones, BM [1 ]
机构
[1] UNIV HONG KONG,DEPT PATHOL,CLIN IMMUNOL SECT,HONG KONG,HONG KONG
关键词
D O I
10.1046/j.1365-3083.1996.d01-4.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Normal human peripheral blood mononuclear cells, depleted of most monocytes and virtually all CD8-positive cells, were stimulated in vitro with pokeweed mitogen plus Staphylococcus nuleus Cowan I in the presence or absence of various neutralizing anti-cytokine antibodies. Numbers of CD5(+) and CD5(-) immunoglobulin-secreting cells were determined using the protein A haemolytic plaque assay after labelling Bla cells with anti-CD5-coated beads. Antibodies against IL-2, IL-5 and IL-10 had little or no effect on plaque-forming cell (PFC) induction; anti-IL-6, -TNF alpha and -TGF beta enhanced PFC induction; anti-IL-1 alpha, -IL-1 beta, -IL-4, -IFN gamma and -IL-13 suppressed PFC induction. Bla and B2 cells were equally affected by cytokine deprivation using these 11 neutralizing antibodies. In contrast, neutralizing anti-IL-12 suppressed induction of CD5(+) but not CD5(-) PFC. Furthermore, recombinant IL-12, if added during the first 48 h of culture, enhanced CD5(+) PFC induction while marginally suppressing (IgG-) or not affecting (IgA-, IgM-) induction of CD5(-) PFC. IL-12 did not preferentially increase survival in culture of Bla cells nor induce expression of CD5 on B2-cells. Further studies are required to determine whether manipulation of Bla and B2 subsets in vivo using IL-12 could be achieved in clinical situations where imbalances in the two populations have been observed.
引用
收藏
页码:64 / 72
页数:9
相关论文
共 31 条
[1]  
AVRAMEAS S, 1991, IMMUNOL TODAY, V12, P154
[2]  
BONA CA, 1988, ANNU REV IMMUNOL, V6, P327, DOI 10.1146/annurev.iy.06.040188.001551
[3]   AN ANTIGEN SHARED BY A HUMAN T-CELL SUBSET AND B-CELL CHRONIC LYMPHOCYTIC LEUKEMIC-CELLS - DISTRIBUTION ON NORMAL AND MALIGNANT LYMPHOID-CELLS [J].
BOUMSELL, L ;
COPPIN, H ;
PHAM, D ;
RAYNAL, B ;
LEMERLE, J ;
DAUSSET, J ;
BERNARD, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1980, 152 (01) :229-234
[4]   TUMOR-NECROSIS-FACTOR-ALPHA IS AN AUTOCRINE GROWTH-FACTOR FOR NORMAL HUMAN B-CELLS [J].
BOUSSIOTIS, VA ;
NADLER, LM ;
STROMINGER, JL ;
GOLDFELD, AE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (15) :7007-7011
[5]  
CASALI P, 1989, ANNU REV IMMUNOL, V7, P513, DOI 10.1146/annurev.iy.07.040189.002501
[6]   CD5+ LYMPHOCYTE-B, POLYREACTIVE ANTIBODIES AND THE HUMAN B-CELL REPERTOIRE [J].
CASALI, P ;
NOTKINS, AL .
IMMUNOLOGY TODAY, 1989, 10 (11) :364-368
[7]   IL-13 INDUCES PROLIFERATION AND DIFFERENTIATION OF HUMAN B-CELLS ACTIVATED BY THE CD40-LIGAND [J].
COCKS, BG ;
MALEFYT, RD ;
GALIZZI, JP ;
DEVRIES, JE ;
AVERSA, G .
INTERNATIONAL IMMUNOLOGY, 1993, 5 (06) :657-663
[8]   NATURAL AUTOANTIBODIES MIGHT PREVENT AUTOIMMUNE-DISEASE [J].
COHEN, IR ;
COOKE, A .
IMMUNOLOGY TODAY, 1986, 7 (12) :363-364
[9]  
DESAI BB, 1992, J IMMUNOL, V148, P3125
[10]  
FREEDMAN AS, 1989, BLOOD, V73, P202